Roche Launches Axelios 1, an NGS Platform Targeting Illumina's Dominant Genomics Market
Roche, a global leader in diagnostics, has launched Axelios 1, a new Next-Generation Sequencing (NGS) platform that directly challenges Illumina's dominance in the NGS market. This launch marks Roche's first major foray into the NGS market since its failed $6.8 billion hostile takeover bid for Illumina in 2012. Axelios 1 is initially designed for the Research Use Only (RUO) market, with plans for future expansion into clinical diagnostics. The launch demonstrates Roche's strong strategic commitment to disrupting Illumina's monopoly, which currently controls approximately 70% of the global genomics market.
The core strength of Axelios 1 lies in Roche's successful integration of technologies from acquired biotech companies. By combining the sensor technology of Genia Technologies and the chemical technology of Stratos Genomics, Roche has developed a unique Sequencing by Expansion (SBX) technology. This technology converts genetic material into Xpandomers, which have a high signal-to-noise ratio, and then precisely measures them using a CMOS sensor. This streamlined process reduces the need for complex pre-processing steps, enabling Whole-Genome Sequencing to be completed in as little as one day, significantly increasing research efficiency.
To ensure the rapid adoption of its new platform, Roche has established strategic partnerships with leading players in the precision medicine industry. The company has partnered with 10x Genomics, a leader in single-cell analysis, to develop dedicated assay kits, and has integrated Google's DeepVariant software to enhance data analysis reliability. Furthermore, Roche is collaborating with leading research institutions, such as Broad Clinical Labs, to conduct initial validation studies and establish the academic credibility of the platform. These partnerships are designed to build a strong user ecosystem, which is crucial for success in the competitive NGS market, and to lower the initial barriers to entry.
Roche has priced Axelios 1 at $750,000 in the US market, positioning it as a direct competitor to Illumina's NovaSeq X series. The company aims to install approximately 100 units in major research laboratories worldwide in the first year, and ultimately generate over 1 billion Swiss francs (CHF, approximately $1.1 billion) in annual revenue. While currently limited to research applications, Roche plans to leverage the data generated from academic research to obtain regulatory approval for clinical use, thereby regaining market share. This strategic move by Roche is expected to reshape the genomics market, accelerate the adoption of precision medicine, and ultimately benefit patients.
Roche's launch of Axelios 1 marks a significant shift in the global NGS market, which is currently dominated by Illumina with a 70% market share. The market is projected to reach approximately $10 billion by 2026. In the short term, Axelios 1, priced at $750,000 per unit, will compete directly with Illumina's NovaSeq X series, driving down sequencing costs and lowering the barriers to entry for research institutions. The combination of SBX technology with 10x Genomics and Google DeepVariant will provide researchers with faster and more efficient whole-genome sequencing capabilities. In the long term, Roche aims to expand beyond the RUO market and obtain regulatory approval for clinical diagnostic applications, positioning itself as a leader in the hospital and diagnostics market and driving the adoption of precision medicine in standard of care.